Physician profile
Johan Koo
NPI 1114280419
$1,735.69
in general payments reported to CMS, 2019-2025
24 companies · $583 in 2025
The $583 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.85 · 2023: $281 · 2024: $854 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,716.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $250.01 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.45 | 2023-2025 | Jardiance, Ofev |
| Astrazeneca Pharmaceuticals Lp | $188.44 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $158.74 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $104.90 | 2024-2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $102.77 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.80 | 2023-2024 | |
| Abbvie INC. | $92.36 | 2023-2024 | |
| Pfizer INC. | $81.15 | 2023-2025 | |
| Axsome Therapeutics, INC. | $64.36 | 2025 | Auvelity |
| Dexcom, INC. | $44.33 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $38.65 | 2024 | Trelegy Ellipta, Arexvy |
| Esperion Therapeutics, INC. | $38.41 | 2023-2024 | Nexletol |
| Phathom Pharmaceuticals, INC. | $34.51 | 2024-2025 | Voquezna |
| Eisai INC. | $33.82 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $30.07 | 2023-2024 | Livalo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.12 | 2025 | Caplyta |
| Amgen INC. | $25.54 | 2024 | Krystexxa |
| Sanofi-Aventis U.S. LLC | $21.40 | 2025 | |
| Verity Pharmaceuticals INC. | $20.94 | 2025 | Tlando |
| Genentech USA, INC. | $18.85 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.43 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.96 | 2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $14.68 | 2023 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johan Koo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.